Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Sep 30;14(16):6301–6318. doi: 10.7150/thno.98671

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Characterization of EVs from colorectal cancer patients using the plasmapheresis protocol. The PDEVs exhibited size distribution, shape, EV-specific marker expression comparable to the PDEVs used in previous experiments. A) NTA of particle size distribution of PDEVs. The lines represent the mean of 5 readings. Details on the size distribution and concentration are provided in Table 4. B) Immunoblot analysis of TSG101 (47 KDa) expression in plasma-derived EVs from patients (lane 1: patient 1; lane 2: patient 2; lane 3: patient 3; lane 4: patient 4). C) Representative EV morphology and size obtained by cryo electron microscopy. Scale bar: 100 nm. D) Flow cytometry analysis of CFSE-labeled PDEVs showing the percentage (>80%) of CFSE-positive (CFSE+) vesicles. The cytogram depicts the side scatter (SSC)-A vs B3-A (green fluorescence triggering) used to trace the CFSE+ gate. CFSE, carboxyfluorescein succinimidyl ester; PDEVs, patient-derived extracellular vesicles.